Implementing Automation and Flexible Design for Allogeneic Manufacturing
Abstract: As cell therapies advance toward commercialization, the industry is increasingly prioritizing manufacturing optimization and capacity. Allogeneic “off-the-shelf” therapies, derived from healthy donors or renewable sources, offer significant advantages over patient-specific autologous treatments by decoupling manufacturing from individual patients. This shift enables larger batch production, reduced costs, and improved patient access. To address complexities like immunogenicity and regulatory requirements, manufacturers are adopting flexible facility designs and sophisticated automation. While automation enhances consistency and reduces human error, its implementation must be carefully balanced with the need for process flexibility during early-stage clinical development.